Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Maze Therapeutics (MAZE) has drawn fresh attention after recent trading, with the stock closing at $46.01 and showing mixed short term moves, including a 1 day decline and a modest gain over the past week.
See our latest analysis for Maze Therapeutics.
For context, Maze Therapeutics has a 30 day share price return of 11.92% and a 90 day share price return of 41.44%, while its 1 year total shareholder return of 283.42% suggests strong recent momentum rather than fading interest.
If this kind of move in a clinical stage biotech has caught your eye, it could be a good moment to see what else is setting the pace in healthcare, starting with 25 healthcare AI stocks.
With Maze trading near US$46.01 and sitting only about 7% below one analyst price target of US$49.44, the question is whether there is still an edge here or the market is already pricing in future growth.
At $46.01, Maze Therapeutics is trading on a P/B of 5.8x, which looks cheap against its peer group but expensive compared to the broader US pharmaceuticals space.
P/B compares the market value of the company to its net assets, which is a common way to look at early stage biopharma companies that are not yet profitable. For Maze, this lens is relevant because it currently reports a net loss of $101.458m and less than $1m in revenue, so earnings-based metrics are not very informative.
Relative to closely matched peers, Maze screens as good value, with its 5.8x P/B sitting below a peer average of 15.5x. That suggests the market is putting a lower value on each dollar of Maze’s net assets than on peers, which some investors may view as a discount for a business still expected to remain unprofitable over the next three years despite strong revenue growth expectations.
Compared with the wider US pharmaceuticals industry, however, Maze looks expensive, as the sector average P/B sits at 2.4x. That gap is wide, and it indicates that the market is currently willing to pay more than twice the typical industry multiple for Maze, possibly reflecting its clinical pipeline and forecasts of faster revenue growth rather than its current financials.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price to book of 5.8x (ABOUT RIGHT)
However, this picture can change quickly if clinical trial results disappoint or funding needs increase, especially given annual net losses of $101.458m and minimal reported revenue.